GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Tedizolid phosphate (Sivextro)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Sivextro

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

SIVEXTRO - adult ABSSSI dosing

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
No renal-function dose bands specified for this summary.

Dosing / renal protocol and limits

Adult acute bacterial skin/skin-structure infection: 200 mg orally or IV once daily for 6 days. Give IV doses over 1 hour. IV-to-oral conversion does not change the dose. No renal adjustment is required, including during hemodialysis; dialysis does not meaningfully remove tedizolid.

Longer treatment is not the labeled course. Consider hematologic monitoring for prolonged off-label therapy. This adult card does not reproduce the label's separate pediatric weight-based schedules.

Source revision: DailyMed updated 2026-02-27. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

SIVEXTRO - adult ABSSSI dosing

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - tedizolid

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Qualitative no-adjustment guidance.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, 5th edition - Tedizolid phosphate

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Handbook source

Renal Drug Handbook, 5th edition - Tedizolid phosphate

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

Historical renal / replacement-therapy guidanceRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeSIVEXTRO - adult ABSSSI dosingUCSF - tedizolidRenal Drug Handbook, 5th edition - Tedizolid phosphate
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9

Product and population scope

Adult Tedizolid phosphate (Sivextro). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-tedizolid · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

SIVEXTRO - adult ABSSSI dosing

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2026-02-27.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult acute bacterial skin/skin-structure infection: 200 mg orally or IV once daily for 6 days. Give IV doses over 1 hour. IV-to-oral conversion does not change the dose. No renal adjustment is required, including during hemodialysis; dialysis does not meaningfully remove tedizolid.

Longer treatment is not the labeled course. Consider hematologic monitoring for prolonged off-label therapy. This adult card does not reproduce the label's separate pediatric weight-based schedules.

RDM30-077-tedizolid-1 · Source locator: SIVEXTRO - adult ABSSSI dosing; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9
Retrieved
2026-09-05
DailyMed Set ID
75672079-589f-451a-bdbf-eaebcfcc80a9
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2026-02-27.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
6c774b07076be5513d6f2c7d596b5c51c38ba3feb1498c2465a484b192ec1251
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Tedizolid phosphate

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. The listed regimen is 200 mg once daily for 6 days. PD removal is described as absent and HD removal below 10%; usual dosing is retained. High-flux/continuous removal is unknown, although the book retains usual dosing. These are historical RRT statements, not contemporary measured clearance for every circuit.

HB30-tedizolid-1 · Source locator: Printed page 964: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 964; uploaded PDF p. 983
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
9fedee0734f04af544fa6b44938ea81fdfd02a941b42225fbd329b4767c02b3f
Separate professional-source layer

University and professional protocols

Professional

UCSF - tedizolid

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Qualitative no-adjustment guidance.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

The adult institutional regimen is 200 mg IV or orally once daily. No reduction is recommended solely for renal dysfunction or hemodialysis. Duration and indication must be selected separately; this renal summary does not extend the approved treatment course.

RDM30-037-tedizolid-1 · Source locator: UCSF - tedizolid; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/tedizolid
Retrieved
2026-09-05
Renal-function method
Qualitative no-adjustment guidance.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
2e68418779a8726efcdce1785f2a97d19bcb6221846aa635820752937edb3610

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
3e8e145c2fb329c05ca6b070f5e7894783fb4fb068ad85409d9b87aa686318c9
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report